The chemokine CXCL16 and its receptor, CXCR6, as markers and promoters of inflammation-associated cancers.
Clinical observations and mouse models have suggested that inflammation can be pro-tumorigenic. Since chemokines are critical in leukocyte trafficking, we hypothesized that chemokines play essential roles in inflammation-associated cancers. Screening for 37 chemokines in prostate cancer cell lines and xenografts revealed CXCL16, the ligand for the receptor CXCR6, as the most consistently expressed chemokine. Immunohistochemistry and/or immunofluorescence and confocal imaging of 121 human prostate specimens showed that CXCL16 and CXCR6 were co-expressed, both on prostate cancer cells and adjacent T cells. Expression levels of CXCL16 and CXCR6 on cancer cells correlated with poor prognostic features including high-stage and high-grade, and expression also correlated with post-inflammatory changes in the cancer stroma as revealed by loss of alpha-smooth muscle actin. Moreover, CXCL16 enhanced the growth of CXCR6-expressing cancer and primary CD4 T cells. We studied expression of CXCL16 in an additional 461 specimens covering 12 tumor types, and found that CXCL16 was expressed in multiple human cancers associated with inflammation. Our study is the first to describe the expression of CXCL16/CXCR6 on both cancer cells and adjacent T cells in humans, and to demonstrate correlations between CXCL16 and CXCR6 vs. poor both prognostic features and reactive changes in cancer stoma. Taken together, our data suggest that CXCL16 and CXCR6 may mark cancers arising in an inflammatory milieu and mediate pro-tumorigenic effects of inflammation through direct effects on cancer cell growth and by inducing the migration and proliferation of tumor-associated leukocytes.
Darash-Yahana
Merav
M
Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), Bethesda, MD, USA. meravd@hadassah.org.il
Gillespie
John W
JW
Hewitt
Stephen M
SM
Chen
Yun-Yun K
YY
Maeda
Shin
S
Stein
Ilan
I
Singh
Satya P
SP
Bedolla
Roble B
RB
Peled
Amnon
A
Troyer
Dean A
DA
Pikarsky
Eli
E
Karin
Michael
M
Farber
Joshua M
JM
D014408:Biomarkers, Tumor / Q000378:metabolism*; D015496:CD4-Positive T-Lymphocytes / Q000166:cytology; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC / Q000378:metabolism*; D004797:Enzyme-Linked Immunosorbent Assay; D006801:Humans; D007150:Immunohistochemistry; D007249:Inflammation / Q000150:complications*; D008297:Male; D011471:Prostatic Neoplasms / Q000150:complications / Q000378:metabolism*; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine / Q000378:metabolism*; D051116:Receptors, Scavenger / Q000378:metabolism*; D011991:Receptors, Virus / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction
D014408:Biomarkers, Tumor; C423727:CXCL16 protein, human; C106330:CXCR6 protein, human; D000075743:Chemokine CXCL16; D019743:Chemokines, CXC; D000075744:Receptors, CXCR6; D019707:Receptors, Chemokine; D051116:Receptors, Scavenger; D011991:Receptors, Virus
Cancer Lett. 2007 Oct 28;256(2):137-65
17629396
Arterioscler Thromb Vasc Biol. 2005 Apr;25(4):791-6
15604417
Nat Rev Cancer. 2004 Jul;4(7):540-50
15229479
Cancer Res. 2007 May 15;67(10):4725-31
17510400
Lancet. 2001 Feb 17;357(9255):539-45
11229684
Nat Immunol. 2000 Oct;1(4):298-304
11017100
FASEB J. 2004 Aug;18(11):1240-2
15180966
Ann N Y Acad Sci. 2001 Dec;947:199-205; discussion 205-6
11795267
Nature. 1997 Jul 17;388(6639):296-300
9230441
J Biol Chem. 2000 Dec 29;275(52):40663-6
11060282
Cancer Sci. 2008 Jul;99(7):1362-9
18452560
Cell. 2004 Aug 6;118(3):285-96
15294155
J Immunol. 2005 Jan 1;174(1):277-83
15611250
Arthritis Rheum. 2005 Oct;52(10):3004-14
16200580
Clin Exp Allergy. 2005 Dec;35(12):1572-80
16393323
Cancer Res. 2008 Dec 15;68(24):10367-76
19074906
J Exp Med. 1997 Jun 2;185(11):2015-23
9166430
Cell. 2005 May 6;121(3):335-48
15882617
J Pathol. 2006 Nov;210(3):363-73
16955398
PLoS Biol. 2005 Apr;3(4):e113
15799695
J Neurochem. 2005 Jun;93(5):1293-303
15934948
Pharmacol Rev. 2000 Mar;52(1):145-76
10699158
Cancer Res. 2008 Jun 15;68(12):4701-8
18559516
Arterioscler Thromb Vasc Biol. 2004 Apr;24(4):750-5
14988089
Mol Cancer Res. 2008 Apr;6(4):546-54
18344492
J Immunol. 2001 Apr 15;166(8):5145-54
11290797
Arthritis Rheum. 2006 Mar;54(3):765-78
16508941
Biochem Biophys Res Commun. 2004 Dec 24;325(4):1187-93
15555552
Carcinogenesis. 2005 Jul;26(7):1170-81
15498784
Hum Pathol. 2007 May;38(5):768-80
17306330
Semin Cancer Biol. 2005 Apr;15(2):132-7
15652458
Ann Med. 2004;36(2):98-118
15119830
Anticancer Res. 2000 Nov-Dec;20(6A):4073-80
11131675
Am J Respir Crit Care Med. 2005 Nov 15;172(10):1290-8
16100013
Cell. 2005 Jul 1;121(7):977-90
15989949
Eur J Cancer. 2006 Apr;42(6):760-7
16510278
Biochem Biophys Res Commun. 2002 Nov 15;298(5):675-86
12419307
Nature. 2002 Dec 19-26;420(6917):860-7
12490959
Cancer Cell. 2005 Mar;7(3):211-7
15766659
Breast Cancer Res. 2007;9(4):212
17705880
Nat Rev Cancer. 2006 Jan;6(1):24-37
16397525
Methods. 2001 Dec;25(4):402-8
11846609
J Intern Med. 2005 May;257(5):415-22
15836657
World J Gastroenterol. 2005 Aug 28;11(32):4979-85
16124049
Infect Immun. 2005 Jul;73(7):4007-16
15972488
Atherosclerosis. 2006 Oct;188(2):462-6
16378611
Am J Pathol. 1999 Dec;155(6):1985-92
10595928
J Clin Invest. 2001 Mar;107(5):595-601
11238560
Cancer Res. 2008 Dec 1;68(23):9996-10003
19047182
Nature. 2004 Sep 23;431(7007):461-6
15329734
J Immunol. 2008 Sep 1;181(5):3099-107
18713980
J Immunol. 2005 Jan 15;174(2):1055-62
15634930
J Immunol. 2003 Sep 15;171(6):2960-9
12960320